Payment overview · 2025
General Payments
$775.47
42 reported records · 18 companies
Healthcare provider profile · identity verified
Tejas Navnit Mehta, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HUMBLE, TX · NPI 1518956143
Verified facts
What the public records show
CMS Open Payments records show Tejas Navnit Mehta, MD received $775.47 in general payments during 2025 across 42 reported records.
ABBVIE INC. accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $216.21 | 27.9% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $126.87 | 16.4% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.08 | 7.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.25 | 7.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.25 | 4.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.28 | 4.4% | 2 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $32.15 | 4.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $30.72 | 4.0% | 1 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $28.59 | 3.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.27 | 2.7% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $20.72 | 2.7% | 1 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $19.47 | 2.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.83 | 2.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.49 | 2.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.61 | 2.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.00 | 1.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.46 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.22 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $775.47 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $175.48 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $106.34 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $59.08 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $54.42 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $54.25 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $54.25 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $54.25 | 2 | 2025 |
Source payment records
|
|||||
| CURE CATHETER Normalized: cure catheter |
Device | ConvaTec Inc. | $32.15 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $30.72 | 1 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $28.59 | 1 | 2025 |
Source payment records
|
|||||
| Solia Normalized: solia |
Device | BIOTRONIK INC. | $28.59 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $12.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 118 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
118 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 483 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 473 | 150 |
| Losartan Potassium | Losartan Potassium | 470 | 135 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 346 | 110 |
| Pantoprazole Sodium | Pantoprazole Sodium | 345 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 295 | 92 |
| Famotidine | Famotidine | 272 | 98 |
| Meloxicam | Meloxicam | 228 | 70 |
| Gabapentin | Gabapentin | 217 | 81 |
| Metformin Hcl | Metformin Hcl | 216 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 67 |
| Omeprazole | Omeprazole | 198 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 64 |
| Lisinopril | Lisinopril | 184 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 62 |
| Carvedilol | Carvedilol | 176 | 60 |
| Furosemide | Furosemide | 174 | 58 |
| Montelukast Sodium | Montelukast Sodium | 164 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 145 | 44 |
| Celecoxib | Celecoxib | 136 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 22 |
| Ozempic | Semaglutide | 127 | 25 |
| Synthroid | Levothyroxine Sodium | 118 | 33 |
| Valsartan | Valsartan | 118 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 35 |
| Simvastatin | Simvastatin | 113 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 39 |
| Tramadol Hcl | Tramadol Hcl | 96 | 35 |
| Allopurinol | Allopurinol | 93 | 28 |
| Atenolol | Atenolol | 88 | 27 |
| Bupropion Xl | Bupropion Hcl | 83 | 27 |
| Alprazolam | Alprazolam | 82 | 34 |
| Finasteride | Finasteride | 77 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 33 |
| Alendronate Sodium | Alendronate Sodium | 71 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 23 |
| Glimepiride | Glimepiride | 70 | 21 |
| Trazodone Hcl | Trazodone Hcl | 63 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 27 |
| Metformin Hcl Er | Metformin Hcl | 54 | 16 |
| Aripiprazole | Aripiprazole | 52 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 19 |
| Eszopiclone | Eszopiclone | 50 | 15 |
| Potassium Chloride | Potassium Chloride | 50 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 15 |
| Lactulose | Lactulose | 49 | 19 |
| Pregabalin | Pregabalin | 49 | 18 |
| Lorazepam | Lorazepam | 47 | 12 |
| Prednisone | Prednisone | 47 | 36 |
| Ezetimibe | Ezetimibe | 46 | 17 |
| Sertraline Hcl | Sertraline Hcl | 46 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 17 |
| Nifedipine Er | Nifedipine | 40 | 16 |
| Azithromycin | Azithromycin | 39 | 36 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Lovastatin | Lovastatin | 38 | 12 |
| Nitroglycerin | Nitroglycerin | 38 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | 13 |
| Valacyclovir | Valacyclovir Hcl | 37 | 13 |
| Eliquis | Apixaban | 36 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 16 |
| Azelastine Hcl | Azelastine Hcl | 34 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 13 |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 12 |
| Propranolol Hcl | Propranolol Hcl | 33 | 13 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | 11 |
| Methylprednisolone | Methylprednisolone | 29 | 28 |
| Sucralfate | Sucralfate | 29 | 11 |
| Donepezil Hcl | Donepezil Hcl | 27 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 25 |
| Bumetanide | Bumetanide | 26 | 12 |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $775.47 · 42 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AMVIA EDGE, AREXVY, CARDIOMEMS, COMIRNATY, CURE CATHETER, Cologuard Collection Kit, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, JATENZO, KRYSTEXXA, LUNA, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, SYNTHROID, Solia, Sunosi, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, YUPELRI | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error